Gesynta Pharma receives orphan drug designation by FDA for systemic sclerosis
27 Apr 2022 //
PHARMAFILE
Gesynta Pharma receives orphan drug designation by FDA for systemic sclerosis
26 Apr 2022 //
PHARMAFILE
Gesynta Pharma announces development program for its drug candidate GS-248
14 Jun 2021 //
CISION
Gesynta Pharma initiates Phase II study
28 Jan 2021 //
PRESS RELEASE